It will be interesting to see how the generics will attempt to distinguish Cyclobenzaprine when they file their Opposition Brief tomorrow. Then it will be even more interesting to see how Singer attacks that effort on his Reply Brief.
Hamoa great post and stay posting for the longs On the board as your info so far is 100%.We need an amazing mind to take us through this so we can make correct Money decisions going forward.